1 / 16

Shivaani Kummar, MD National Cancer Institute June 3, 2007

Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial. Shivaani Kummar, MD National Cancer Institute June 3, 2007. Poly (ADP-Ribose) Polymerase (PARP). Conducted under the FDA’s Exploratory IND Guidance.

gseldon
Download Presentation

Shivaani Kummar, MD National Cancer Institute June 3, 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial Shivaani Kummar, MD National Cancer Institute June 3, 2007

  2. Poly (ADP-Ribose) Polymerase (PARP)

  3. Conducted under the FDA’s Exploratory IND Guidance Example 3: Clinical Studies of Mechanism of Action (MOA) Related to Efficacy

  4. Objectives • Primary: • Determine a non-toxic dose range at which ABT-888 inhibits PARP in tumor samples and in peripheral blood mononuclear cells (PBMCs) . • Determine the pharmacokinetics of ABT-888. • Determine the time course of PARP inhibition in PBMCs by ABT-888. • Secondary: • Determine the safety of administering one dose of ABT-888.

  5. Eligibility Criteria • Participants with solid tumors must have advanced disease refractory to at least one line of standard therapy or for which no standard therapy is available. • Participants with CLL or lymphoma may be enrolled if they have disease for which standard therapy is currently not indicated or disease that has failed at least one line of standard therapy. • Any prior therapy must have been completed ≥ 2 weeks prior to protocol enrollment. • Adequate organ function.

  6. PBMC Samples 0, 2, 4, 7, 24 hr PK Samples 10 Tumor Biopsies 3-6 Hr Study Schema ABT-888 • Tumor biopsies planned: • Significant PARP inhibition in PBMCs from at least 1 of the 3 participants at a given dose level, OR •  Plasma CMax of 210 nM was achieved in at least 1 participant

  7. Study Schema • The level of PARP expression in both tumor and PBMCs was determined using an ELISA assay prior to proceeding with drug administration and further sampling. • The required minimum level of PAR expression was defined as 31 pg PAR per mL of PBMC extract (allows for demonstration of a 50% reduction in PARP activity) prior to proceeding with sampling for PD studies. • All participants received drug and had sampling for PK studies.

  8. Dose Escalation 3 patients at each dose level The objective of dose escalation was to investigate a PD end-point, i.e. inhibition of PARP activityand not to determine the MTD. Dose escalation continued with the goal to achieve significant PARP inhibition in tumor samples in 3 out of 3 participants at 2 dose levels.

  9. Trial Statistics • Endpoints are PARP inhibition in tumor tissue and in PBMCs. For either endpoint: • Significant PARP inhibition for a dose level is defined as 2-fold reduction in PAR level for at least 2 patients out of the 3 accrued • If there is 80% likelihood of 2-fold reduction in PAR levelfor the patients, thenthere is 90% power to declare significant inhibition for the dose level, by the binomial distribution.

  10. Trial Results (To Date) • 10 patients enrolled on study, 8 are evaluable • 3 patients (10 mg); 3 patients (25 mg); 4 patients (50 mg- 2 NE: tumor biopsy negative for PAR levels at baseline (1), 1 pt withdrew prior to receiving drug due to personal reasons) • Age (range): 49-70 years • Diagnoses: Carcinoid (1), Colorectal cancer (3), small cell lung cancer (1), low grade lymphomas (3), CTCL (1), adenocarcinoma of the external auditory canal (1). • Patients monitored by serial bloodwork, EKGs, physical exams.

  11. Pt 1 Pt 2 Pt 3 Pt 4 Pt 6 Pt 7 Pt 8 Pt 10 PAR Inhibition in PBMCs Cohort 1 Cohort 2 Cohort 3

  12. PAR Inhibition in tumor biopsies

  13. First Phase 0 - Timelines and what we have achieved

  14. First Phase 0 - What Have We Achieved? • Established that ABT-888 inhibits the target of interest at clinically achievable concentrations. • Established target assay feasibility in human samples after qualification in animal models. Assay validated in preclinical models using clinical procedures. • Developed SOPs for human tissue acquisition, handling and processing. • Performed real-time PK and PD analyses (results received within 72 hours of obtaining sample). • PK and PD data, including timing of tumor and PBMC sampling, available well before planned Phase 1 combination studies.

  15. Acknowledgements NCI’s PHASE 0 TEAM James H. Doroshow Jerry Collins Anthony J Murgo Martin Gutierrez Larry Rubinstein Seth Steinberg Richard Chang Anthony Kim Yvonne Horneffer Lamin Juwara Maryann Yancey Janelle Bingham Joseph E. Tomaszewski Robert Kinders Ralph E. Parchment Melinda Hollingshead Jiuping Ji Oxana Pickeral Jennifer Low Larry Phillips Alice Chen Tiziano DiPaolo Sherry Yang Yiping Zhang ABBOTT LABORATORIES All the present and future patient participants of Phase 0 trials

More Related